Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-PanTumor02
2023-504721-39-02Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Dec 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 14
01
Overview
Phase 2, open-label trial of trastuzumab deruxtecan in biliary cancer, bladder cancer, Cervical Cancer (CC) and 4 more (2 arms), sponsored by AstraZeneca. Primary endpoint: Objective response rate. Planned start Dec 2020; status: authorised.
02
Drugs
trastuzumab deruxtecan
03
Conditions
biliary cancerbladder cancerCervical Cancer (CC)endometrial cancer (EC)ovarian cancer
Beyond the preview
Go deeper on 2023-504721-39-02.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504721-39-02.